These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26325492)

  • 1. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
    Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
    Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer.
    Prasad S; Cambridge L; Huguet F; Chou JF; Zhang Z; Wu AJ; O'Reilly EM; Allen PJ; Goodman KA
    Pract Radiat Oncol; 2016; 6(2):78-85. PubMed ID: 26577010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
    Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer.
    Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
    Pract Radiat Oncol; 2016; 6(4):e107-e115. PubMed ID: 27032572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
    Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
    Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
    Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy.
    Kruser TJ; Rice SR; Cleary KP; Geye HM; Tome WA; Harari PM; Kozak KR
    Technol Cancer Res Treat; 2013 Oct; 12(5):383-9. PubMed ID: 23547974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
    Koerber SA; Slynko A; Haefner MF; Krug D; Schoneweg C; Kessel K; Kopp-Schneider A; Herfarth K; Debus J; Sterzing F
    Radiat Oncol; 2014 May; 9():113. PubMed ID: 24886574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
    Yovino S; Poppe M; Jabbour S; David V; Garofalo M; Pandya N; Alexander R; Hanna N; Regine WF
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):158-62. PubMed ID: 20399035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Golden DW; Novak CJ; Minsky BD; Liauw SL
    Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer.
    Samuelian JM; Callister MD; Ashman JB; Young-Fadok TM; Borad MJ; Gunderson LL
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1981-7. PubMed ID: 21477938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
    Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
    BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic Toxicity of Conformal Radiotherapy and Intensity Modulated Radiotherapy in Prostate and Bladder Cancer Patients.
    Miszczyk M; Majewski W
    Asian Pac J Cancer Prev; 2018 Oct; 19(10):2803-2806. PubMed ID: 30360609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
    Woo SM; Kim MK; Joo J; Yoon KA; Park B; Park SJ; Han SS; Lee JH; Hong EK; Kim YH; Moon H; Kong SY; Kim TH; Lee WJ
    Cancer Res Treat; 2017 Oct; 49(4):1022-1032. PubMed ID: 28111423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.